GLPG

Investor Moves

Investor	Portfolio Value	Portfolio Change	Position Change	Avg Buy Price	Current Price
Jim SimonsRenaissance Technologies $-8.6K ExitQ2 2024 $8.6k -- --

News

seekingalpha.comGalapagos NV (GLPG) Q1 2026 Earnings Call Transcriptseekingalpha.comMay 7

globenewswire.comGalapagos Reports First Quarter 2026 Financial Results and Provides Business Updateglobenewswire.comMay 6

globenewswire.comGalapagos' Shareholders Adopt All Resolutions Proposed by the Board of Directors at the Annual and Extraordinary Shareholders' Meetings 2026globenewswire.comApr 28

defenseworld.netGalapagos (NASDAQ:GLPG) Stock Crosses Below 200 Day Moving Average – Time to Sell?defenseworld.netApr 8

globenewswire.comGalapagos en Gilead gaan definitieve overeenkomst aan over samenwerking om een first-in-class T-cel-engagerprogramma voor auto-immuunziekten verder te ontwikkelenglobenewswire.comMar 31

Trade GLPG

About Galapagos N.V.

Galapagos NV functions as an integrated biopharmaceutical enterprise, concentrating its efforts on identifying, developing, and marketing a diverse range of medications aimed at critical unaddressed medical conditions. The company's comprehensive pipeline includes several significant experimental therapies. Leading this portfolio is filgotinib, a JAK1 inhibitor that is currently progressing through various clinical trial phases for the management of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel Crohn's disease, fistulizing Crohn's disease, ankylosing spondylitis, psoriatic arthritis, and uveitis. Additionally, their developmental assets feature GLPG1972, which has successfully completed its Phase 2b trial for osteoarthritis. A series of "Toledo" compounds, namely GLPG3970, GLPG4399, and GLPG4876, are in development for inflammatory conditions. GLPG4716 and Ziritaxestat are also part of the pipeline, targeting idiopathic pulmonary fibrosis. Further pipeline advancements include GLPG2737, a cystic fibrosis transmembrane conductance regulator undergoing Phase 2 clinical trials for patients afflicted with autosomal dominant polycystic kidney disease. Another JAK1 inhibitor, GLPG0555, is in Phase 1b development for osteoarthritis. Galapagos NV has established collaborative agreements with major industry players such as Gilead Sciences, Inc., AbbVie S.à r.l., and Novartis Pharma AG. The company was established in 1999 and its headquarters are located in Mechelen, Belgium.

CEO: Henry Gosebruch
IPO Date: Feb 27, 2012

Market Data

Open: $27.50
High: $28.09
Low: $27.50
Volume: 2.4K
52W High: $37.78
52W Low: $24.74

Valuation

Market Cap: $1.8B
Enterprise Value: $1.6B

Financials

Free Cash Flow: $-202M
Revenue: $1.1B
Net Income: $321M
Cash: $88M
Debt: $6.9M

Events

EarningsAug 10

EPS est. -0.96723